MAM
Policy with a pulse Kotadia joins FICCI to shape India’s Medtech moment
MUMBAI: When healthcare meets policy, the stakes are anything but clinical. India’s fast-growing medical devices sector has added a new voice at the table with the appointment of Bhargav Kotadia as co-chair of FICCI’s Medical Devices Committee.
Founded in 1927, the Federation of Indian Chambers of Commerce and Industry (FICCI) has long been a bridge between government, industry, academia and research institutions. Within that ecosystem, its Medical Devices Committee plays a central role in shaping India’s MedTech agenda, from regulation and manufacturing to innovation and global competitiveness.
Accepting the appointment, Kotadia thanked FICCI president Anant Goenka and reiterated Sahajanand Medical Technologies’ commitment to the sector. He pointed to the scale of opportunity ahead, noting that industry estimates peg India’s medical devices market at around USD 30 billion by 2030, making it one of the country’s most promising growth engines over the next decade.
That growth, he said, aligns closely with the prime minister’s Viksit Bharat vision, as India positions itself as a global hub for healthcare manufacturing and innovation. With sustained collaboration between industry and government, Kotadia added, the focus will be on strengthening the MedTech ecosystem, improving global competitiveness and driving sustainable, innovation-led expansion.
Beyond the appointment itself, SMT is expected to remain actively involved in the committee’s work, contributing to policy formulation, stakeholder consultations and thought leadership. The company has, in recent years, played a visible role in discussions around regulatory reform, import substitution, R&D enhancement, Free Trade Agreements and the adoption of advanced technologies in healthcare delivery.
SMT’s continued leadership presence within FICCI underscores a broader shift in India’s medical devices narrative: from dependency to design, from imports to innovation. As policy frameworks evolve and ambitions scale up, the committee’s work will help determine how quickly and confidently India’s MedTech story moves from potential to practice.
